Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The annual burden of illness for GI bleeding in the U.S. is $7.5 billion.1 GI bleeding should be suspected in patients who present with anemia, melena, or hematochezia. Every year, in the U.S., 4.4 million patients present with suspected GI bleeding, but up to 10% remain undiagnosed following EGD/colonoscopy.2,3
Radiofrequency ablation is a minimally-invasive procedure aimed to treat bleeding by providing coagulation in conditions such as gastric antral vascular ectasia (GAVE) and radiation proctitis (RP). The Barrx™ SB RFA endoscopic catheter is an innovative through-the-scope catheter that delivers RFA energy for small bowel bleeding.
The Barrx™ SB RFA endoscopic catheter delivers:
Peery A, Dellon E, Lund J, Crockett S, Mcgowan C, Bulsiewicz W, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179-87.
Zhu A, Kaneshiro M, Kaunitz J. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. Digestive Disease Sciences. 2010;55:548-559.
Internal Data–Internal Market Model. July, 2015. Data on file.
Barrx SB RFA Ablation Catheter: Design Validation Report #V-0400-02, 01, 26, 2018, data on file, based on animal study.
Internal Medtronic report, Barrx SB RFA Ablation Catheter: Design Verification Report #V-0399-03, 01, 26, 2018, data on file, based on animal lab study.
Internal Medtronic report, Barrx SB RFA Ablation Catheter: Design Verification Report #V-0399-03, 01, 26, 2018, data on file, based on animal lab study.
Images do not represent all components of the system.